Clinical Trial Search

Primary: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure…

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL — 68 Subjects

Primary: Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6 — 0.566; 0.761; 0.468 Proportion of Subjects — p=0.1298

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within +- 1 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter During…

Primary: Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3) — 188.9; 173.6; 165.9 units on a scale — p=0.190

Primary: Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device — 15.0; 14.8 micrograms/milliliter (µg/mL)

Primary: Annual Rate of Serious Bacterial Infections — 0.020 Estimated infections/year — p=<0.0001

Primary: Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6. — 0.554; 0.665; 0.233 Proportion of Subjects — p=<0.0001

Primary: Average Rhinoconjunctivitis Total Symptom Score (ARTSS) — 3.25; 4.51 Units on a scale (range: 0 to 18) — p=0.0010

Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33

Primary: Average Adjusted Symptom Score (AAdSS) — 5.58; 6.07 Units on a scale (range: 0 to 18) — p=0.2344

Primary: Average Adjusted Symptom Score (AAdSS) — 3.39; 3.25; 5.21 Units on a scale (range: 0 to 18) — p=< 0.0001

Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036

Primary: Overall Survival — 14.26; 17.51; 12.68; 16.20 months